Lonza, BioWa Sign Licensing Agreement - - BioPharm International

ADVERTISEMENT

Lonza, BioWa Sign Licensing Agreement



BioWa and Lonza have entered into a licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca, under which  MedImmune has licensed the companies’ Potelligent CHOK1SV cell line technology for use in multiple proprietary antibodies in its pipeline.

Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System.  The GS System includes Lonza’s host cell line, CHOK1SV.  Potelligent Technology is designed to improve the potency and efficacy of therapeutic antibodies by improving antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of therapeutic antibodies.

MedImmune entered into a previous licensing agreement with BioWa in 2007 for Potelligent Technology.   Today’s agreement incorporates Lonza’s technology to the existing Potelligent Technology.

Source: Lonza

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here